All In Biotech

Drug Trial Radar · NCT06728553

Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults

A Pilot, Phase 2a, Randomized, Double-blind, Placebo-controlled, Cross-over Clinical Study to Evaluate Safety and Efficacy of Sublingual MTX101 for the Acute Treatment of Migraine Headaches in Adults

Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

78

Actual

Start

Feb 24, 2025

Primary completion

Jun 27, 2025

Study completion Jul 28, 2025

Sponsor

Lead sponsor
Manistee TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101. The main questions it aims to answer are: Does the drug MTX101 lower headache pain for participants and the need to use a rescue medication? What side effects, if any, do participants have when taking the drug MTX101? Researchers will compare the drug MTX101 to a placebo (a look-alike substance that contains no drug) to see if the drug MTX101 works to treat acute migraine attacks. Participants will: Take the drug MTX101 or a placebo to treat 1 migraine attack with each treatment. Visit the clinic twice and have one phone call over a 4 week period for checkups and tests. Keep a diary of their symptoms and the number of times they use a rescue medication.

Conditions

  • Migraine

Interventions

  • MTX101Drug

    One 2 mg sublingual tablet of MTX101

  • PlaceboDrug

    One sublingual tablet of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety assessment (occurrence of adverse events, treatment emergent adverse events and serious adverse events).Time frame: Treatment emergent adverse event safety assessments will be limited to the first 48 hours after a treated attack.

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Kaizen Brain Center

    La Jolla, California

  • Clinical Research Institute, LLC

    Santa Monica, California

  • Brainstorm Research

    Miami, Florida

  • Synergy Clinical Research/Emerald Coast Center for Neurological Disorders

    Pensacola, Florida

  • DelRicht Research

    New Orleans, Louisiana

  • QUEST Research Institute

    Farmington Hills, Michigan

  • Wasatch Clinical Research

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.